Segments

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

SEGMENTS

SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended March 31,
(In thousands)	2023		2022
Revenue from services:
Pharmaceutical	$	—	$	—
Diagnostics	132,368		286,599
Corporate	—		—
	$	132,368	$	286,599
Revenue from products:
Pharmaceutical	$	40,383	$	36,658
Diagnostics	—		—
Corporate	—		—
	$	40,383	$	36,658
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	64,826	$	5,962
Diagnostics	—		—
Corporate	—		—
	$	64,826	$	5,962
Operating income (loss):
Pharmaceutical	$	18,955	$	(18,108)
Diagnostics	(40,007)		(43,548)
Corporate	(9,542)		(10,768)
	$	(30,594)	$	(72,424)
Depreciation and amortization:
Pharmaceutical	$	17,760	$	15,402
Diagnostics	8,686		12,412
Corporate	—		—
	$	26,446	$	27,814
Loss from investment in investees:
Pharmaceutical	$	(37)	$	(49)
Diagnostics	—		—
Corporate	—		—
	$	(37)	$	(49)
Revenues:
United States	$	189,085	$	291,808
Ireland	15,846		8,462
Chile	15,541		16,339
Spain	6,110		7,109
Israel	4,594		1,558
Mexico	5,826		3,750
Other	575		193
	$	237,577	$	329,219

(In thousands)	March 31, 2023		December 31, 2022
Assets:
Pharmaceutical	$	1,373,982	$	1,322,531
Diagnostics	671,875		690,504
Corporate	123,813		154,224
	$	2,169,670	$	2,167,259
Goodwill:
Pharmaceutical	$	314,355	$	312,826
Diagnostics	283,025		283,025
	$	597,380	$	595,851

No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2023 and 2022. As of March 31, 2023 and December 31, 2022, no customer represented more than 10% of our accounts receivable balance.